ArticleFrontiers in endocrinology2025
Effectiveness of preimplantation genetic testing for aneuploidy in improving clinical and neonatal outcomes for patients with recurrent pregnancy loss.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study aimed to evaluate a clinical utility of preimplantation genetic testing for aneuploidy (PGT-A) in patients with recurrent pregnancy loss (RPL) and explore a population that benefits from it. Methods: We analyzed 818 oocyte retrieval cycles and 1,165 frozen embryo transfer cycles from 797 patients with RPL. Stratified analyses were conducted based on age, number of miscarriages, chromosomal polymorphisms and ovarian reserve to compare clinical and perinatal outcomes between PGT-A and non-PGT-A groups. Results: Euploid, aneuploid, and mosaic blastocysts accounted for 54.07%, 33.33%, and 12.60%, respectively. Age stratification analysis showed that PGT-A significantly improved the clinical pregnancy rate (CPR) and live birth rate (LBR) in patients under 38 years (CPR: 63.64% vs. 55.03%, P = 0.004; LBR: 53.03% vs. 43.25%, P = 0.002). In age group of 38 years or older, PGT-A was associated with a higher CPR (50.63% vs. 35.42%, P = 0.034), while the increase in LBR did not reach statistical significance (36.70% vs. 23.96%, P = 0.084). In patients with three previous miscarriages, PGT-A significantly improved CPR (74.70% vs. 42.13%) and LBR (55.42% vs. 32.02%) (P < 0.05). Chromosomal polymorphism analysis revealed that outcomes with PGT-A were superior for patients with normal karyotypes, whereas no significant differences were observed among those with polymorphisms. PGT-A significantly improved CPR (59.68% vs. 52.37%, P = 0.004) and LBR (49.41% vs. 40.56%, P < 0.01) in patients with normal ovarian reserve. Although CPR increased in those with a diminished ovarian reserve (62.50% vs. 39.45%, P = 0.015), this was accompanied by a marked increase in the miscarriage rate (40.00% vs. 23.36%, P = 0.029). Consequently, no statistical difference was noted in LBR. Conclusions: PGT-A can significantly improve CPR and LBR in patients with RPL aged < 38 years with a history of three miscarriages, a normal chromosomal karyotype, and a normal ovarian reserve. For patients with a history of two miscarriages, PGT-A notably enhances a success of clinical pregnancy conversion into live birth. However, for individuals with diminished ovarian reserve, chromosomal polymorphisms, or a history of four or more miscarriages, a cautious and individualized assessment is necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.